Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors

  • Randall E Harris1Email author,
  • Joanne Beebe-Donk1 and
  • Galal A Alshafie1
BMC Cancer20088:237

https://doi.org/10.1186/1471-2407-8-237

Received: 18 October 2007

Accepted: 14 August 2008

Published: 14 August 2008

Abstract

Background

Epidemiologic and laboratory investigations suggest that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive effects against colon cancer perhaps due at least in part to their activity against cyclooxygenase-2 (COX-2), the rate-limiting enzyme of the prostaglandin cascade.

Methods

We conducted a case control study of colon cancer designed to compare effects of selective and non-selective COX-2 inhibitors. A total of 326 incident colon cancer patients were ascertained from the James Cancer Hospital, Columbus, Ohio, during 2003–2004 and compared with 652 controls with no history of cancer and matched to the cases at a 2:1 ratio on age, race, and county of residence. Data on the past and current use of prescription and over the counter medications and colon cancer risk factors were ascertained using a standardized risk factor questionnaire. Effects of COX-2 inhibiting agents were quantified by calculating odds ratios (OR) and 95% confidence intervals.

Results

Results showed significant risk reductions for selective COX-2 inhibitors (OR = 0.31, 95% CI = 0.16–0.57), regular aspirin (OR = 0.33, 95% CI = 0.20–0.56), and ibuprofen or naproxen (0.28, 95% CI = 0.15–0.54). Acetaminophen, a compound with negligible COX-2 activity and low dose aspirin (81 mg) produced no significant change in the risk of colon cancer.

Conclusion

These results suggest that both non-selective and selective COX-2 inhibitors produce significant reductions in the risk of colon cancer, underscoring their strong potential for colon cancer chemoprevention.

Background

Among American men and women, colon cancer is the third most frequently diagnosed malignancy and third leading cause of cancer death [1]. In the past two decades, incidence and mortality rates for colon cancer have declined by more than 20% in women and men [1, 2]. While some authors attribute these downward trends to early detection and more effective therapy [2], the exact reasons are not yet fully understood. One factor that may have contributed to these declines is the widespread intake of aspirin, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs)[3]. Among 22 published epidemiologic studies that focused on the association between intake of NSAIDs and the risk of human colon cancer, 20 reported statistically significant risk reductions. Meta-analysis of these data suggests that regular NSAID intake (primarily aspirin) reduces the risk of colon cancer by about 60% [4].

Two selective COX-2 inhibitors, celecoxib (Celebrex) and rofecoxib (Vioxx), were approved for the treatment of arthritis by the United States Food and Drug Administration (FDA) in 1999 [3]. Until the recall of Vioxx in September, 2004, these two compounds plus other selective COX-2 inhibitors valdecoxib (Bextra) and meloxicam (Mobic) were widely utilized in the United States for pain relief and treatment of osteoarthritis and rheumatoid arthritis [5, 6]. The time period between approval of celecoxib to the recall of rofecoxib provides an approximate six-year window for evaluation of exposure to these compounds by a case control approach. The current case control study was designed to test and compare the chemopreventive value of selective and nonselective COX-2 inhibitors against human colon cancer.

Methods

We studied 326 cases of invasive colon cancer with histological verification based upon review of the pathology records, and 652 group-matched controls with no personal history of cancer and no current gastrointestinal disease. Cases were sequentially ascertained for interview at the time of their diagnosis during 2003 through September, 2004 at The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (CHRI), Columbus, Ohio. There were no refusals to participate among cases. The controls were ascertained from the mammography unit and prostate screening services of the cancer hospital during the same time period and frequency matched to the cases at a rate of 2:1 by five-year age interval, race, and place (county) of residence. We interviewed randomly selected controls from these screening facilities throughout the time frame of the study to achieve a 2:1 ratio by gender, age, race and county of residence. Among men and women approached and eligible for participation, 95% completed the questionnaire. The protocol was approved by the Human Subjects Cancer Internal Review Board of The Ohio State University Medical Center and informed consent documentation was obtained for participants.

Critical information on exposure to NSAIDs and other factors were obtained utilizing a standardized risk factor questionnaire. The questionnaires were administered in person by trained medical personnel (who were blinded as to the purpose of the study) prior to definitive surgery or treatment for the cases and at the time of screening mammography or screening for prostate cancer for controls. The data variables collected consisted of demographic characteristics, height, weight, menstrual and pregnancy history for women, family history of colon cancer, comprehensive information on cigarette smoking, alcohol intake, pre-existing medical conditions (arthritis, chronic headache, cardiovascular conditions including hypertension, angina, ischemic attacks, stroke, and myocardial infarction, lung disease, and diabetes mellitus), and medication history including over the counter (OTC) and prescription NSAIDs, and exogenous hormones. Regarding selective COX-2 inhibitors and other NSAIDs, the use pattern (frequency, dose, and duration), and the type, (celecoxib, valdecoxib, rofecoxib, meloxicam, aspirin, ibuprofen, naproxen, indomethacin) were recorded. Data on the related analgesic, acetaminophen were collected for comparison with selective COX-2 inhibitors and other NSAIDs.

Case-control differences in means and frequencies were checked for statistical significance by t-tests and chi square tests, respectively. Effects of the selective COX-2 inhibitors as a group were quantified by estimating odds ratios and their 95% confidence intervals. Odds ratios were adjusted for age and colon cancer risk factors (family history, body mass, chronic smoking, and regular alcohol intake) by logistic regression analysis [7, 8]. Adjusted estimates were obtained for specific types of compounds, e.g., aspirin, ibuprofen or naproxen, selective COX-2 inhibitors (rofecoxib and celecoxib), and acetaminophen. Estimates for selective COX-2 inhibitors were also adjusted for prior intake of other types of NSAIDs.

Results

Pertinent characteristics of the cases and controls are given in Table 1. The cases exhibited higher frequencies of hypertension (OR = 2.87, 95% CI = 2.10–3.92) family history of colon cancer (OR = 1.58, 95% CI = 1.08–2.30) and chronic cigarette smoking (OR = 2.07, 95% CI = 1.49–2.87). Cases and controls had similar distributions of matching variables, age, gender, race and county of residence as well as education, body mass and alcohol consumption.
Table 1

Characteristics of colon cancer cases and controls.

Characteristic a

Cases (N = 326)

Controls (N = 652)

Gender

  

   Female

45%

45%

Age (yrs)

  

   <50

15%

11%

   50–59

22

25

   60–69

32

34

   >65

31

30

   Mean (SEM)

63.2 (0.7)

63.5 (0.6)

Race

  

   Caucasian

90%

86%

Residence

  

   Franklin County, Ohio

81%

83%

   Adjacent Counties

18

15

   Other

1

2

Education

  

   < 12 yrs

12%

12%

   12 yrs

53

55

   > 12 yrs

35

33

Family History

  

   Positive

20%

13% (p < 0.01)

Body Mass

  

   BMI < 22

14%

12%

   BMI 22–27

32

40

   BMI > 27

55

48

   Mean (SEM)

29.1 (0.5)

28.1 (0.3)

Smoking

  

   (>10 Pack-years)

33%

22% (p < 0.01)

Alcohol Intake

  

   None

47%

45%

   1–2 drinks per week

36

35

   > 2 drinks per week

17

20

Hypertension

47%

28% (p < 0.01)

a Family History: colon cancer among first or second degree relatives; Body Mass Index = weight (kg)/ht 2 (m).

Table 2 shows the comparative frequencies of the medications under study with multivariate-adjusted odds ratios and 95% confidence intervals. A significant reduction in the risk of colon cancer was observed for daily intake of selective COX-2 inhibitors for one year or more (Adjusted OR = 0.31, 95% CI = 0.16–0.57). Joint use of COX-2 inhibitors with aspirin or other NSAIDs was reported by 9.4% of subjects; however, the odds ratio for COX-2 inhibitors was not appreciably changed with additional adjustment for the prior intake of such compounds (OR = 0.40, 95% CI = 0.25–0.82). Estimates for smokers and nonsmokers and subjects with and without hypertension were also similar. When the data were stratified by gender, the risk reduction for the selective COX-2 inhibitors was stronger for women (OR = 0.20, 95% CI = 0.08–0.46) than men (OR = 0.75, 95% CI = 0.29–2.20).
Table 2

Odds ratios with 95% confidence intervals for colon cancer and selective cyclooxygenase-2 (COX-2) inhibitors, and over the counter nonsteroidal anti-inflammatory drugs (OTC NSAIDS).

Compound

Number of Cases (%)

Number of Controls (%)

Multivariate OR d (95% CI)

None/Infrequent Use a

236 (72)

352 (54)

1.00

COX-2 Inhibitors b

15 (5)

53 (8)

0.31 (0.16–0.57)

OTC NSAIDs c

   

   Aspirin

22 (7)

88 (13)

0.33 (0.20–0.56)

   Ibuprofen/Naproxen

13 (4)

68 (11)

0.28 (0.15–0.54)

   Acetaminophen

12 (3)

22 (3)

0.81 (0.35–1.61)

   Baby Aspirin

28 (9)

69 (11)

0.58 (0.35–1.02)

a No use of any NSAID or analgesic or infrequent use of no more than one pill per week for less than one year;

b COX-2 inhibitors include celecoxib, rofecoxib, valdecoxib, and meloxicam used daily for one year or more.

c Over the counter (OTC) NSAIDs/analgesics used at least once per week for more than one year.

d Multivariate odds ratios are adjusted for continuous variables (body mass) and categorical variables (hypertension, family history, smoking, and alcohol intake).

Significant risk reductions were also observed for the intake of one or more pills per week of regular aspirin (OR = 0.33, 95% CI = 0.20–0.56), and ibuprofen or naproxen (0.28, 95% CI = 0.15–0.54). Low dose (81 mg) aspirin produced a risk reduction with marginal significance (OR = 0.58, 95% CI = 0.35–1.20) whereas acetaminophen had no effect on the relative risk of colon cancer. Aspirin was used for cardioprotection by 9% of subjects taking 325 mg tablets compared to 93% of subjects taking 81 mg tablets.

Table 3 presents risk estimates for individual selective COX-2 inhibitors (celecoxib and rofecoxib) plus dose-response data for aspirin and ibuprofen. Daily use of either 200 mg celecoxib or 25 mg rofecoxib for more than one year produced similar risk reductions (65% and 68%, respectively). The average duration of use was 3.6 years. The trend data for OTC compounds suggests that 325 mg aspirin or 200 mg ibuprofen produced significant risk reductions when taken daily for 5 or more years.
Table 3

Odds ratios for colon cancer by dose, frequency, and duration of exposure to celecoxib, rofecoxib, aspirin, and ibuprofen.

Compound a

Dose

Cases

Controls

Frequency of Use

Multivariate OR b (95% CI)

  

N (%)

  

None

0

236 (72)

352 (54)

None

 

Celecoxib

200 mg

8 (2)

27 (4)

Daily

0.35 (0.18–0.93)

Rofecoxib

25 mg

7 (2) 26 (4)

 

Daily

0.32 (0.12–0.83)

Aspirin

325 mg

5 (2)

14 (2)

1–2 weekly

0.87 (0.24–3.17)

  

4 (1)

8 (1)

3–6 weekly

0.73 (0.20–2.67)

  

13 (4)

66 (10)

Daily

0.22 (0.12–0.41)

     

trend (p < 0.05)

Ibuprofen

200 mg

7 (2)

17 (3)

1–2 weekly

0.67 (0.26–1.69)

  

2 (1)

12 (2)

3–6 weekly

0.18 (0.02–1.50)

  

4 (1)

39 (6)

Daily

0.19 (0.07–0.49)

     

trend (p < 0.01)

a Minimum duration of exposure: one year for celecoxib or rofecoxib, 5 years for aspirin or ibuprofen.

b Multivariate odds ratios are adjusted for continuous variables (body mass) and categorical variables (hypertension, family history, smoking, and alcohol intake).

Discussion

Our observation of a significant risk reduction in human colon cancer due to intake of selective COX-2 inhibitors is similar to that reported by Rahme et al. [9]. Standard daily dosages of celecoxib (200 mg) or rofecoxib (25 mg) were associated with a 69% reduction in colon cancer risk. Notably, comparator NSAIDs with non-selective COX-2 activity (325 mg aspirin or 200 mg ibuprofen) also produced significant risk reductions of similar magnitude. In contrast, the effect of low dose aspirin (81 mg) was only marginally significant and acetaminophen, an analgesic with little COX-2 activity, had no effect on the risk of colon cancer.

Selective COX-2 inhibitors (celecoxib and rofecoxib) were only recently approved for use in 1999, and rofecoxib (Vioxx) was withdrawn from the marketplace in 2004 [35]. Nevertheless, even in the short window of exposure to these compounds, the selective COX-2 inhibitors produced significant reductions in the risk of colon cancer, underscoring their strong potential for colon cancer chemoprevention.

In general, NSAIDs inhibit cyclooxygenase which is the key rate-limiting enzyme of prostaglandin biosynthesis [1012]. Molecular studies show that the inducible COX-2 gene is over-expressed in human colon cancer and that genetic expression of COX-2 in cancer cells is correlated with mutagenesis, mitogenesis, angiogenesis, and deregulation of apoptosis [1315]. Over the counter NSAIDs have consistently shown antitumor effects in animal models of carcinogenesis [16], and striking antitumor effects of the specific COX-2 inhibitor, celecoxib, have been observed against colon cancer [17]. Epidemiologic studies and randomized clinical trials provide convincing evidence that regular intake of aspirin and other NSAIDs not only inhibit the development of colon cancer per se, but also interrupt the evolution of preneoplastic lesions of the colonic mucosa [18]. Furthermore, recent randomized clinical trials of selective COX-2 inhibitors indicate that celecoxib suppresses the development of colon adenomas [19, 20]. The current study coupled with existing clinical, preclinical and molecular evidence suggest that aberrant induction of COX-2 and up-regulation of the prostaglandin cascade play a significant role in colon carcinogenesis, and that blockade of this process has strong potential for intervention. It is noteworthy that NSAIDs also manifest anticancer effects by mechanisms other than COX-2 inhibition [21]. For example, celecoxib has been found to have multiple COX-independent anticancer effects including induction of apoptosis and inhibition of cell cycle progression, angiogenesis, and metastasis [21, 22]. Thus, it will be important to exploit not only COX-2 blockade but also COX-independent molecular targets of these compounds [22].

Enthusiasm for the use of selective COX-2 blocking agents in the chemoprevention of colon cancer and other malignancies has been tempered by reports of adverse effects on the cardiovascular system leading to the recall of the popular anti-arthritic compound, rofecoxib (Vioxx) [2325], and subsequently, the cardiovascular safety of all selective COX-2 inhibitors has come under scrutiny [5]. However, such studies involved supra-therapeutic dosages given over long periods of time without consideration of body size or individual differences in metabolism [26]. Nevertheless, not all studies reflect changes in cardiovascular risk with exposure to COX-2 inhibitors [27, 28] and recently a large meta-analysis of existing randomized clinical trials found no risk increase at any dose level of celecoxib [29]. Further studies will be required to determine the appropriate dose, frequency of intake, duration, side effects and cost effectiveness of selective and nonselective COX-2 inhibitors in the chemoprevention of cancer.

Conclusion

We observed a significant reduction in the risk of human colon cancer due to intake of both selective and nonselective COX-2 inhibitors. Chemopreventive effects against colon cancer were associated with recommended daily doses of celecoxib (median dose = 200 mg) or rofecoxib (median dose = 25 mg) for an average duration of 3.6 years. Notably, the regular intake of over the counter NSAIDs such as aspirin and ibuprofen produced risk reductions in colon cancer similar in magnitude to the selective COX-2 inhibitors.

Declarations

Acknowledgements

The authors thank Elvira M. Garofalo, Program Manager of the James Cancer Mammography Unit, and Julie M. Coursey, Assistant Director of the James Cancer Medical Records Registry, for their assistance in the conduct of this investigation. Funding organizations were not involved in study design, collection, analysis and interpretation of data or manuscript preparation and the decision to submit the manuscript for publication.

Authors’ Affiliations

(1)
The Ohio State University College of Medicine and Public Health

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun JM: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66.View ArticlePubMedGoogle Scholar
  2. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, Schrag D, Jamison PM, Jemal A, Wu XC, Friedman C, Harlan L, Warren J, Anderson RN, Pickle LW: Annual report to the nation on the status of cancer, 1975-featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005, 97 (19): 1407-1427.View ArticlePubMedGoogle Scholar
  3. Rainsford KD: Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007, 42: 3-27.View ArticlePubMedGoogle Scholar
  4. Harris RE, Beebe-Donk J, Doss H, Burr-Doss D: Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (Review). Oncol Rep. 2005, 13 (4): 559-583.PubMedGoogle Scholar
  5. Couzin J: Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science. 2004, 306: 384-385.View ArticlePubMedGoogle Scholar
  6. Couzin J: Clinical Trials: Nail-biting time for trials of drugs. Science. 2004, 306: 1673-1675.View ArticlePubMedGoogle Scholar
  7. Schlesselman JJ: Case Control Studies. 1982, Oxford University Press, New YorkGoogle Scholar
  8. Harrell F: Logistic Regression Procedure. 2005, Statistical Analysis System (SAS)Google Scholar
  9. Rahme E, Barkun AN, Goubouti Y, Bardolu M: The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology. 2003, 125 (2): 404-412.View ArticlePubMedGoogle Scholar
  10. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971, 231: 323-235.Google Scholar
  11. Herschman HR: Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer and Metas Rev. 1994, 13: 241-256.View ArticleGoogle Scholar
  12. Hla T, Neilson K: Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992, 89: 7384-7388.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN: Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenoma and adenocarcinoma. Gastroenterology. 1994, 107: 1183-1188.View ArticlePubMedGoogle Scholar
  14. Sano H, Kawahito Y, Wilder R, Hashiramotot A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T: Expression of cylcooxygenase-1 and -2 in colorectal cancer. Cancer Res. 1995, 55: 3785-3789.PubMedGoogle Scholar
  15. Masferrer JL, Leahy KM, Koki AT, Aweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60 (5): 1306-1311.PubMedGoogle Scholar
  16. Reddy BS, Chinthalapally RV: Role of synthetic and naturally occurring cyclooxygenase inhibitors in colon cancer prevention. COX-2 Blockade in Cancer Prevention and Therapy. Edited by: Harris RE. 2002, Humana Press, Totowa, NJ, 71-83.View ArticleGoogle Scholar
  17. Reddy BS: Strategies for colon cancer prevention: combination of chemopreventive agents. Subcell Biochem. 2007, 42: 213-25. ReviewView ArticlePubMedGoogle Scholar
  18. Harris RE: Cyclooxygenase-2 (COX-2) and the inflammogenesis of cancer. Subcell Biochem. 2007, 42: 93-126. ReviewView ArticlePubMedGoogle Scholar
  19. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET, APC Study Investigators: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006, 355 (9): 873-884.View ArticlePubMedGoogle Scholar
  20. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B, PreSAP Trial Investigators: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006, 355 (9): 885-895.View ArticlePubMedGoogle Scholar
  21. Kashfi K, Rigas B: Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol. 2005, 70 (7): 969-986.View ArticlePubMedGoogle Scholar
  22. Grosch S, Maier TJ, Schiffmann S, Geisslinger G: Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006, 98 (11): 736-747.View ArticlePubMedGoogle Scholar
  23. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc. 2001, 286 (8): 954-959.View ArticleGoogle Scholar
  24. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005, 352 (11): 1092-1102.View ArticlePubMedGoogle Scholar
  25. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005, 352 (11): 1071-1080.View ArticlePubMedGoogle Scholar
  26. Harris RE: Does the dose make the poison?. Science. 2005, 308: 203-View ArticlePubMedGoogle Scholar
  27. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002, 89 (4): 425-430.View ArticlePubMedGoogle Scholar
  28. White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor, celecoxib. Am J Cardiol. 2003, 92 (4): 411-418.View ArticlePubMedGoogle Scholar
  29. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM: Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007, 99 (1): 91-98.View ArticlePubMedGoogle Scholar
  30. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/237/prepub

Copyright

© Harris et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement